(Q35561670)

8 August 2017

1 reference

title

Cytokine-directed therapies for the treatment of chronic airway diseases (English)

1 reference

8 August 2017

1 reference

https://api.crossref.org/works/10.1016/S1359-6101(03)00058-3

22 March 2024

1

Peter J. Barnes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14563353

22 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14563353

22 March 2024

publication date

1 December 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S1359610103000583?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1359-6101(03)00058-3

https://api.elsevier.com/content/article/PII:S1359610103000583?httpAccept=text/plain

22 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1359-6101(03)00058-3

Cytokine and Growth Factor Reviews

22 March 2024

published in

1 reference

8 August 2017

volume

14

1 reference

8 August 2017

issue

6

1 reference

8 August 2017

page(s)

511-522

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

8 August 2017

1 reference

7 January 2021

Mechanisms in COPD: differences from asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Cytokine modulators as novel therapies for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

New treatments for COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Inhibitory cytokines in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Endogenous inhibitory mechanisms in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Biology of interleukin-5 and its relevance to allergic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Characterization of YM-90709 as a novel antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Airway subepithelial fibrosis in a murine model of atopic asthma: suppression by dexamethasone or anti-interleukin-5 antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Efficacy of soluble IL-4 receptor for the treatment of adults with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

An immune cell-selective interleukin 4 agonist

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

IL-4/IL-13 signaling beyond JAK/STAT

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

STAT6: an intracellular target for the inhibition of allergic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Interleukin-13 in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Interleukin-13 induces a hypersecretory ion transport phenotype in human bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Critical role for IL-13 in the development of allergen-induced airway hyperreactivity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Interleukin-13: central mediator of allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Interleukin-9 receptor expression in asthmatic airways In vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Th2 cytokines and asthma. Interleukin-9 as a therapeutic target for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Mast cells produce interleukin-25 upon Fc epsilon RI-mediated activation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Expression of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Interleukin-1 receptor antagonist: role in biology

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Biologic activities of IL-1 and its role in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

The potential role of tumour necrosis factor alpha in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Infliximab: a review of its use in the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Etanercept: a review of its use in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

IL-10: a potential therapy for allergic inflammation?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Interleukin-10 regulation in normal subjects and patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

IL-10: a key regulator of allergic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

CD4 T-helper cells engineered to produce IL-10 prevent allergen-induced airway hyperreactivity and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Role of interleukin 10 in specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Adenovirus-mediated interferon gamma gene therapy for allergic asthma: involvement of interleukin 12 and STAT4 signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

The effects of nebulized recombinant interferon-gamma in asthmatic airways

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Treatment with IFN-alpha in corticosteroid-unresponsive asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Role of chemokines in the pathogenesis of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

The biology of chemokines and their receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Chemokine receptors: multifaceted therapeutic targets

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Non-redundant functional groups of chemokines operate in a coordinate manner during the inflammatory response in the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endobronchial allergen challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

CCR8 is not essential for the development of inflammation in a mouse model of allergic airway disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

The interrelationship of sputum inflammatory markers in patients with chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Interleukin-8 receptor antagonists in pulmonary diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Neutrophilic inflammation in severe persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Transcription factors of the NFAT family: regulation and function

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Effect of suplatast tosilate (IPD-1151T) on cytokine production by allergen-specific human Th1 and Th2 cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Tokyo Joshi-Idai Asthma Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Kinase regulation in inflammatory response

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Differential IκB Kinase Activation and IκBα Degradation by Interleukin-1β and Tumor Necrosis Factor-α in Human U937 Monocytic Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-kappa B-independent mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Inhibition of p38 MAP kinase as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2803%2900058-3

7 January 2021

Inflammatory mediators of asthma: an update

series ordinal

1

1 reference

https://api.crossref.org/works/10.1016/S1359-6101(03)00058-3

Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice

22 March 2024

series ordinal

19

1 reference

https://api.crossref.org/works/10.1016/S1359-6101(03)00058-3

Expression of RANTES mRNA and protein in airways of patients with mild asthma

22 March 2024

series ordinal

83

1 reference

https://api.crossref.org/works/10.1016/S1359-6101(03)00058-3

22 March 2024

Identifiers

1 reference

8 August 2017

1 reference